title: Future therapeutic options for celiac disease.
abstract: Celiac disease is a disorder of the small intestine caused by an inappropriate immune response to wheat gluten and similar proteins of barley and rye. At present, the only available treatment is a strict gluten-exclusion diet; hence the need for alternative treatments. Recent advances have improved our understanding of the molecular basis for this disorder and there are several attractive targets for new treatments. Oral enzyme supplementation is designed to accelerate gastrointestinal degradation of proline-rich gluten, especially its proteolytically stable antigenic peptides. Complementary strategies aiming to interfere with activation of gluten-reactive T cells include the inhibition of intestinal tissue transglutaminase activity to prevent selective deamidation of gluten peptides, and blocking the binding of gluten peptides to the HLA-DQ2 or HLA-DQ8 molecules. Other possible treatments include cytokine therapy, and selective adhesion molecule inhibitors that interfere with inflammatory reactions, some of which are already showing promise in the clinic for other gastrointestinal diseases.
authors.affiliation: University of Oslo and Rikshopitalet University Hospital, Norway. l.m.sollid@medisin.uio.no
authors.forename: Ludvig M
authors.initials: LM
authors.lastname: Sollid
authors.forename: Chaitan
authors.initials: C
authors.lastname: Khosla
mesh_terms: D002446:Celiac Disease / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D016207:Cytokines / Q000627:therapeutic use*; D019587:Dietary Supplements; D005983:Glutens / Q000276:immunology / Q000378:metabolism; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology; D010447:Peptide Hydrolases / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D016207:Cytokines; D005983:Glutens; D010447:Peptide Hydrolases